{
    "nctId": "NCT00928330",
    "briefTitle": "Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy",
    "officialTitle": "A Phase Ib, Open-Label Study of the Safety, Tolerability, Pharmacokinetics, and Activity of Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy",
    "overallStatus": "COMPLETED",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 57,
    "primaryOutcomeMeasure": "Changes in cardiac function",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically documented locally advanced or metastatic breast cancer that has progressed on at least one trastuzumab-based regimen in the metastatic or locally advanced setting\n* HER2-positive disease documented by one of the following results using FDA-approved testing methods: FISH-positive, chromogenic in situ hybridization (CISH)-positive, or IHC 3 + by local laboratory assessment\n* Life expectancy \\>= 90 days\n* Agreement to use an effective form of contraception for the duration of the study\n\nExclusion Criteria:\n\n* History of Grade \\>= 3 hypersensitivity reaction to trastuzumab, or Grade \\>= 1 with the most recent trastuzumab infusion before study entry, or continued requirement for prolonged trastuzumab infusions to prevent hypersensitivity reactions\n* History of intolerance to trastuzumab and/or adverse events related to trastuzumab that resulted in trastuzumab being permanently discontinued\n* Prior anti-cancer therapy (e.g., biologic or other targeted therapy, chemotherapy, hormonal therapy) within 2 weeks prior to Day 1\n* Prior investigational anti-cancer therapy within 4 weeks prior to Day 1\n* Grade \\>= 2 peripheral neuropathy\n* History of Grade \\>= 3 hyperglycemia (fasting)\n* History of Type 1 or Type 2 diabetes requiring daily medication\n* History of clinically significant cardiac or pulmonary dysfunction\n* History of malabsorption syndrome or other condition that would interfere with enteral absorption\n* Clinically significant history of liver disease, including cirrhosis, current alcohol abuse, or current known active infection with HIV, hepatitis B virus, or hepatitis C virus\n* Any condition requiring anticoagulants, such as warfarin, heparin, or thrombolytic agents\n* Any condition requiring \\> 2 grams of acetaminophen daily\n* Need for current chronic corticosteroid therapy\n* Pregnancy, lactation, or breast-feeding\n* Current severe, uncontrolled systemic disease (e.g., clinically significant cardiovascular, pulmonary, or metabolic disease)\n* Major surgical procedure or significant traumatic injury within 28 days prior to Day 1, or anticipation of the need for major surgery during the course of study treatment\n* Symptomatic hypercalcemia requiring continued use of bisphosphonate therapy\n* Known brain metastases that are untreated, symptomatic, or require therapy to control symptoms",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}